Table 2 Sensitivity analysis by excluding the ODYSSEY LONG TERM trial
Intervention | All-cause mortality | Serious adverse events |
|---|---|---|
RR (95% CrI) | RR (95% CrI) | |
Compared with placebo | ||
 Alirocumab | 0.84 [0.73, 0.97] | 0.94 [0.90, 0.99] |
 Evolocumab | 1.04 [0.91, 1.18] | 1.00 [0.96, 1.04] |
 Inclisiran | 1.00 [0.58, 1.72] | 0.92 [0.81, 1.04] |
Compared with alirocumab | ||
 Evolocumab | 1.24 [1.02, 1.50] | 1.06 [1.00, 1.13] |
 Inclisiran | 1.18 [0.67, 2.08] | 0.98 [0.85, 1.12] |
Compared with evolocumab | ||
 Inclisiran | 0.96 [0.55, 1.68] | 0.92 [0.80, 1.05] |